Celltrion

Phone: +82-32-850-5000

E-mail: BusinessDevelopment@celltrion.com

Web: https://www.celltrion.com/

Type	Public
Traded as	KRX: 068270
Industry	Biopharmaceutical
Founded	2002 (2002)
Founder	Jung Jin Seo
Headquarters	Yeonsu-gu, Incheon, South Korea
Area served	Worldwide
Key people	Jung Jin Seo, Chairman Woo Sung Kee, CEO
Products	Remsima™, Truxima™, Herzuma™, Biosimilar Drug
Revenue	₩828,917 million (2017)
Operating income	₩517,385 million (2017)
Net income	₩403,181 million (2017)
Total assets	₩3,255,319 million (2017)
Total equity	₩2,522,076 million (2017)
Owner	Celltrion Holdings Co., Ltd. (23.03%) Ion Investments B.V. (9.54%) National Pension Service (6.07%)
Subsidiaries	Celltrion Entertainment
Website	www.celltrion.com/en

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.

For detailed contact information visit location pages below.